Journal article

IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study

Iddo Paldor, Katharine J Drummond, Andrew H Kaye

JOURNAL OF CLINICAL NEUROSCIENCE | ELSEVIER SCI LTD | Published : 2016

Abstract

Isocitrate dehydrogenase 1 (IDH1) mutation is a known prognostic factor in glioblastoma multiforme (GBM). It has been well documented that patients with IDH1 mutant (IDH1-mu) GBM have a better outcome compared to patients with IDH1 wild-type (IDH1-WT) GBM. IDH1-mu tumors have been shown to be more commonly located in the frontal lobe, and less likely to be in multiple lobes. It is unclear whether differential location is part of the prognostically favorable profile of these tumors. We performed a case-control study, matching IDH1-mu GBMs to IDH1-WT GBMs that are controlled for age, sex and tumor location. There were 21 IDH1-mu tumors and 21 matched IDH1-WT tumors. Age, sex and tumor location..

View full abstract